A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects

Refractory B-cell Acute Lymphoblastic Leukemia, Childhood Clinical Trial

Official title: A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma Subjects

Status Active, not recruiting

Clinical Trial Summary

This is a single arm, open-label, uni-center, phase I/II study to determine the safety and efficacy of an experimental therapy called BinD19 cells in childhood patients with B-cell acute lymphoblastic leukemia or lymphoma, who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic stem cell transplant.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Lymphoma
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Refractory B-cell Acute Lymphoblastic Leukemia, Childhood
• Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood
• Relapsed/Refractory B-cell Lymphoma, Childhood

• NCT number: NCT03265106
• Study type: Interventional
• Source: Shenzhen BinDeBio Ltd.
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: November 1, 2016
• Completion date: December 30, 2021